Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXCM 
DexCom Inc (DXCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: DXCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $88.44
1 Year Target Price $88.44
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.54% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.83B USD | Price to earnings Ratio 32.34 | 1Y Target Price 88.44 |
Price to earnings Ratio 32.34 | 1Y Target Price 88.44 | ||
Volume (30-day avg) 26 | Beta 1.48 | 52 Weeks Range 56.45 - 93.25 | Updated Date 10/31/2025 |
52 Weeks Range 56.45 - 93.25 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When After Market | Estimate 0.57 | Actual 0.61 |
Profitability
Profit Margin 13.29% | Operating Margin (TTM) 18.37% |
Management Effectiveness
Return on Assets (TTM) 6.08% | Return on Equity (TTM) 22.83% |
Valuation
Trailing PE 32.34 | Forward PE 25.64 | Enterprise Value 25704795806 | Price to Sales(TTM) 6.22 |
Enterprise Value 25704795806 | Price to Sales(TTM) 6.22 | ||
Enterprise Value to Revenue 5.98 | Enterprise Value to EBITDA 24.74 | Shares Outstanding 392155265 | Shares Floating 389519982 |
Shares Outstanding 392155265 | Shares Floating 389519982 | ||
Percent Insiders 0.41 | Percent Institutions 96.7 |
Upturn AI SWOT
DexCom Inc
Company Overview
History and Background
DexCom Inc. was founded in 1999 and is headquartered in San Diego, California. It has evolved from developing glucose monitoring systems to becoming a leading provider of continuous glucose monitoring (CGM) systems, significantly impacting diabetes management.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: DexCom's primary business revolves around the design, development, and commercialization of CGM systems for people with diabetes. These systems track glucose levels continuously, providing real-time data to users.
Leadership and Structure
DexCom Inc. is led by CEO Kevin Sayer. The organizational structure includes departments for research and development, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Dexcom G7 CGM System: Dexcom G7 is a continuous glucose monitoring (CGM) system that automatically sends glucose readings to a compatible display device or smart phone every five minutes. Competitors include Abbott's FreeStyle Libre and Medtronic's Guardian Sensor.
- Dexcom G6 CGM System: The Dexcom G6 CGM system provides real-time glucose readings without fingersticks. It is a slightly older model, but continues to be used. Competitors include Abbott's FreeStyle Libre and Medtronic's Guardian Sensor.
Market Dynamics
Industry Overview
The diabetes care market is growing due to the rising prevalence of diabetes globally. Advancements in technology and increased awareness of diabetes management are driving demand for CGM systems.
Positioning
DexCom Inc. holds a leading position in the CGM market, known for its accurate and user-friendly technology. Its competitive advantage lies in its innovation, data insights, and integration capabilities with other diabetes management tools.
Total Addressable Market (TAM)
The TAM for diabetes monitoring is estimated to be in the tens of billions of dollars annually. DexCom is well-positioned to capture a significant portion of this market with its advanced CGM technology and expanding customer base.
Upturn SWOT Analysis
Strengths
- Innovative CGM technology
- Strong brand recognition
- Extensive data analytics capabilities
- Direct-to-consumer sales model
- Partnerships with insulin pump manufacturers
Weaknesses
- High price point compared to traditional blood glucose meters
- Reliance on third-party payers for reimbursement
- Potential for sensor inaccuracies
- Limited product diversification
Opportunities
- Expanding into international markets
- Developing closed-loop insulin delivery systems
- Integrating CGM data with telehealth platforms
- Creating solutions for pre-diabetes management
Threats
- Increasing competition from other CGM manufacturers
- Changes in reimbursement policies
- Technological disruptions
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Medtronic (MDT)
Competitive Landscape
DexCom Inc. competes with Abbott and Medtronic in the CGM market. DexCom differentiates itself through its innovative technology, ease of use, and data insights.
Growth Trajectory and Initiatives
Historical Growth: DexCom Inc. has experienced significant revenue growth in recent years due to the increasing adoption of CGM technology.
Future Projections: Analysts expect DexCom Inc. to continue growing at a rapid pace, driven by new product launches and expansion into new markets.
Recent Initiatives: Recent initiatives include the launch of Dexcom G7 and partnerships with various healthcare providers and technology companies.
Summary
DexCom is a strong company in the CGM market with innovative technology and a leading market position. Its revenue growth is fueled by new products and expansion. Challenges include competition, reimbursement pressures, and the need for continuous innovation. Overall, DexCom is well-positioned for future success, but it must maintain its competitive edge and adapt to evolving market dynamics.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Financial Reports
- Market Research Reports
- Analyst Estimates
- Company SEC Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and analysis are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DexCom Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2005-04-14 | Interim CEO, President & COO Mr. Jacob Steven Leach | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10200 | Website https://www.dexcom.com |
Full time employees 10200 | Website https://www.dexcom.com | ||
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.